By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fluidigm reported after the close of the market Tuesday that its second-quarter revenues increased 32 percent, which the firm attributed to strong sales of its BioMark and Access Array products.

The South San Francisco, Calif.-based firm brought in total revenues of $10.6 million for the three months ended June 30, compared to revenues of $8 million for the second quarter of 2010. Its product revenues were up 30 percent year over year to $9.7 million from $7.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.